Cargando…

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

BACKGROUND: Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumour sensitivity to retinoids. The objective of this study was to determine the safety, tolerability, and the pharmacokinetic (PK)/pharmacodynamic (PD) profiles of the HDAC inhibitor entinostat in combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pili, R, Salumbides, B, Zhao, M, Altiok, S, Qian, D, Zwiebel, J, Carducci, M A, Rudek, M A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251867/ https://www.ncbi.nlm.nih.gov/pubmed/22134508 http://dx.doi.org/10.1038/bjc.2011.527

Ejemplares similares

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
por: Shen, Li, et al.
Publicado: (2012)

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
por: Freundt, Johanna K., et al.
Publicado: (2019)

The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016)

Erratum: The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016)

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
por: Tanioka, Maki, et al.
Publicado: (2018)

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras
por: Cross, Jasmine M., et al.
Publicado: (2022)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Entinostat, a histone deacetylase inhibitor, increases the population of IL-10(+) regulatory B cells to suppress contact hypersensitivity
por: Min, Keun Young, et al.
Publicado: (2021)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
por: Wang, Jiani, et al.
Publicado: (2021)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
por: Bachmann, Luisa M., et al.
Publicado: (2023)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo
por: Milanovic, Dusan, et al.
Publicado: (2015)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Revisiting entinostat as an immune-potentiating adjuvant
por: McCaw, Tyler R., et al.
Publicado: (2018)

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
por: Hicks, Kristin C., et al.
Publicado: (2021)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
por: Lassen, U, et al.
Publicado: (2010)

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat
por: Blagitko-Dorfs, Nadja, et al.
Publicado: (2013)

Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6
por: Liu, Helene Minyi, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
por: Razak, A R A, et al.
Publicado: (2011)

Targeting SALL4 by entinostat in lung cancer
por: Yong, Kol Jia, et al.
Publicado: (2016)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.
por: Formelli, F., et al.
Publicado: (1997)

The influence of duloxetine on detrusor overactivity in rats with depression induced by 13-cis-retinoic acid
por: Wróbel, Andrzej, et al.
Publicado: (2017)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
por: Xu, Binghe, et al.
Publicado: (2023)

Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat
por: Ponthan, F, et al.
Publicado: (2001)

13-Cis Retinoic Acid Activates Regenerative Behavior of Primary Human Lymphatic Endothelial Cells
por: Hsu, Jerry, et al.
Publicado: (2021)

13-cis-retinoic acid inhibits the self-renewal, migration, invasion and adhesion of cholangiocarcinoma cells
por: Butsri, Siriwoot, et al.
Publicado: (2023)

The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury
por: Ning, Li, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
por: Brazelle, William, et al.
Publicado: (2010)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3pa6ldkc4cllrs0uj0emrhinmc